en · de · es · pt
peptide-index.peptides5388.com › Info › Regulation, Testing, And Storage — Reference Sheet

Regulation, Testing, And Storage — Reference Sheet

By Editorial Desk · published 2025-07-16 · last reviewed 2025-07-31 · Info

research compound comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicine in major jurisdictionsSold as a research chemical; legal status varies
Anti-doping statusProhibited by the World Anti-Doping AgencyListed under non-approved substances or related category
Typical analytical methodLC-MS/MSUsed for detection and confirmation in biological samples
Storage temperature−20 °C or lower for solidDesiccated and protected from light
Common solution solventsDMSO; ethanolAqueous solubility is limited

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Related pages on this site

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Handling, Analysis, and Regulation

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Supporting material

== Figurative uses == The use of the word "juice" to mean "liquor" (alcohol) dates from 1828. The use of the term "juice" to mean "electricity" dates from 1896. As a verb, the word "juice" was first recorded as meaning "to enliven" in 1964. The adjective "juiced" is recorded as meaning "drunk" in 1946 and "enhanced or as if enhanced by steroids" in 2003. The adjective "juicy" has meant "succulent" since the 15th century (e.g., a juicy roast beef). The figurative meaning "wealthy, full of some desired quality" dates from the 1620s (e.g., a pirate calling a heavily laden ship he aims to plunder a "juicy catch"). The meaning "lively, suggestive, racy, sensational" (e.g., a juicy scandal) is from 1883.

The game won several publication awards, as well as "Computer Action Game of the Year" from the Academy of Interactive Arts & Sciences during the 3rd Annual Interactive Achievement Awards. The editors of PC Gamer US presented Opposing Force with their 1999 "Best Expansion Pack" award, and nominated it as 1999's overall best game of the year, although it lost the latter prize to Homeworld. They wrote that Opposing Force "makes history by becoming the first expansion pack to be considered for Game of the Year. Yes, it really is that good."

=== Cancer === A 2016 literature review showed that PCT has good value in diagnosing infections in oncologic patients. Moreso, it is especially effective in diagnosing major life threatening episodes in cancer patient such as bacteremia and sepsis. Procalcitonin is reliable to monitor recurrence of medullary thyroid carcinoma. In detecting cancer recurrence, PCT had a sensitivity and specificity of 96% and 96% respectively.

Sources: en.wikipedia.org

Notes from published material

== Legal status == As of March 2022, the European Commission has taken new measures to control the psychoactive substance of 3-CMC. This decision is based on a risk assessment conducted by the EU Drugs Agency (EMCDDA) in November 2021. Since 3-CMC was prohibited in China (October 2015), it was found that most of the production was manufactured in India and little of the substance supply originates from inside Europe. Several European countries were ahead of the European Commission report by (generically) controlling the substance. Nowadays, in almost all countries 3-CMC is prohibited.

==== Molecular fingerprints ==== A molecular fingerprint is a binary vector, where each position corresponds to a specific molecular property. In this representation, a given position X may encode the presence or absence of a particular substructure, with '1' indicating presence and '0' indicating absence. Various types of molecular fingerprints exist, including PubChem CACTVS fingerprints, Klekota-Roth fingerprints, MACCS fingerprints, and Extended-Connectivity Fingerprints (ECFP). A molecular fingerprint can be deterministically computed from a given molecular structure. Different molecular structures may yield the same molecular fingerprint.

is the fraction of all possible contacts that involves an infectious and susceptible individual. (This is mathematically similar to the law of mass action in chemistry in which random collisions between molecules result in a chemical reaction and the fractional rate is proportional to the concentration of the two reactants.) Between I and R, the transition rate is assumed to be proportional to the number of infectious individuals which is

=== Fermentation === Possibly the world's oldest fermented beverage, dating from 9,000 years ago, mead ("honey wine") is the alcoholic product made by adding yeast to honey-water must and fermenting it for weeks or months. The yeast Saccharomyces cerevisiae is commonly used in modern mead production. Mead varieties include drinks called metheglin (with spices or herbs), melomel (with fruit juices, such as grape, specifically called pyment), hippocras (with cinnamon), and sack mead (high concentration of honey), many of which have been developed as commercial products numbering in the hundreds in the United States. Honey is also used to make mead beer, called "braggot".

Sources: en.wikipedia.org

Background from the literature

Between the summer of 2009 and March 2010, the use of mephedrone grew rapidly in the UK, with it becoming readily available at music festivals, head shops and on the internet. A survey of Mixmag readers in 2009, found it was the fourth most popular street drug in the United Kingdom, behind cannabis, cocaine, and ecstasy. The drug was used by a diverse range of social groups. Whilst the evidence was anecdotal, researchers, charity workers, teachers and users reported widespread and increasing use of the drug in 2009. The drug's rapid growth in popularity was believed to be related to both its availability and legality. In a book about drugs David Nutt reports the re-popularization story of mephedrone in a way that can be cross referenced with a report by Chemistry World in an article. Fiona Measham, a criminologist at the University of Lancaster, thought the emergence of mephedrone was also related to the decreasing purity of ecstasy and cocaine on sale in the UK, a view reinforced in a report by the National Treatment Agency for Substance Misuse. The average cocaine purity fell from 60% in 1999 to 22% in 2009 and about half of ecstasy pills seized in 2009 contained no MDMA, and by June 2010 almost all ecstasy pills seized in the UK contained no MDMA. A similar pattern was observed in the Netherlands, with the number of ecstasy tablets containing no MDMA rising from 10% in mid-2008 to 60% by mid-2009, with mephedrone being detected in 20% of ecstasy tablets by mid-2009.

All darmstadtium isotopes are extremely unstable and radioactive; in general, the heavier isotopes are more stable than the lighter. The most stable known darmstadtium isotope, 281Ds, is also the heaviest known darmstadtium isotope; it has a half-life of 14 seconds. The isotope 279Ds has a half-life of 0.18 seconds, while the unconfirmed 281mDs has a half-life of 0.9 seconds. The remaining isotopes and metastable states have half-lives between 1 microsecond and 70 milliseconds. Some unknown darmstadtium isotopes may have longer half-lives, however. Theoretical calculation in a quantum tunneling model reproduces the experimental alpha decay half-life data for the known darmstadtium isotopes. It also predicts that the undiscovered isotope 294Ds, which has a magic number of neutrons (184), would have an alpha decay half-life on the order of 311 years; exactly the same approach predicts a ~350-year alpha half-life for the non-magic 293Ds isotope, however.

Eating (also known as feeding or consuming) is the ingestion of food for digestion. In biology, this is typically done to provide heterotrophic organisms with the essential nutrients and energy needed for metabolism and physical growth, since they are incapable of acquiring nutrition and energy intrinsically like autotrophs and therefore must ingest external organic matters in order to survive. Animals, in particular, have evolved different forms of eating — carnivores and scavengers eat flesh (meat) from other animals, herbivores and algivores eat plants and algae, omnivores consume a mixture of both plant and animal matters, and detritivores and coprophages eat detritus and feces. Animals and phagotrophs eat and digest food internally, as opposed to decomposers such as fungi and microbes, who secrete enzymes to digest organic matters externally before absorbing the nutrients and thus do not "eat" food. For humans, eating is more complex, but is typically an activity of daily living. Human eating is usually organized into routine sessions known as meals, where proper courses of cooked food are consumed, typically with a decent quantity of staples; and more time-flexible casual eatings known as snacks, where small quantities of typically non-staple food (often convenience food, sometimes raw foods such as fruits and nuts) are consumed more for the purpose of degustation than to satiate hunger. Formal sessions of eating, e.g.

== Chemical properties == The substance is a constant mixture of two collagenases (AUX-I and AUX-II) with known amino acid sequences and a length of about 1000 amino acids each. It is prepared by anaerobic fermentation from a strain of C. histolyticum that has been known since 1950.

== Research == Deslorelin was under development for the treatment of endometriosis, polycystic ovary syndrome, precocious puberty, prostate cancer, and uterine fibroids in humans and reached phase III clinical trials for prostate cancer but development was discontinued for all of these indications by 2001.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

How is SR9009 detected?

Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.

How should SR9009 be stored?

Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network